Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint, Genomics Collaborative to Study Pharmacogenomics of Chemotherapy Response

NEW YORK, Nov. 14 (GenomeWeb News) - DNAPrint Genomics and SeraCare Life Sciences' Genomics Collaborative division plan to identify genetic factors associated with how cancer patients respond to carboplatin/tamoxifen-based chemotherapy, DNAPrint said today.


The alliance will study 200 women to compare responses to a standard carboplatin/tamoxifen regimen for breast cancer, according to Hector Gomez, chairman and chief medical officer of DNAPrint.


"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," Kevin Krenitsky, senior vice president and division head of Genomics Collaborative, said.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.